<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: GSK Official Discusses Pharma Partnering</title>
	<atom:link href="http://blog.pharmtech.com/2008/03/27/gsk-official-discusses-pharma-partnering/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.pharmtech.com/2008/03/27/gsk-official-discusses-pharma-partnering/</link>
	<description>The blog of Pharmaceutical Technology magazine</description>
	<lastBuildDate>Thu, 09 May 2013 23:30:55 -0400</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Partnering Profiles: GlaxoSmithKline &#171; Silico Research</title>
		<link>http://blog.pharmtech.com/2008/03/27/gsk-official-discusses-pharma-partnering/comment-page-1/#comment-21811</link>
		<dc:creator>Partnering Profiles: GlaxoSmithKline &#171; Silico Research</dc:creator>
		<pubDate>Thu, 15 Oct 2009 08:46:34 +0000</pubDate>
		<guid isPermaLink="false">http://blog.pharmtech.com/?p=55#comment-21811</guid>
		<description>[...] Annual Report for 2008 GSK entered into or expanded 21 new drug discovery alliances in 2007. Overall 40 per cent of GSK’s pipeline is derived from licensing, acquisition, or other types of [...]</description>
		<content:encoded><![CDATA[<p>[...] Annual Report for 2008 GSK entered into or expanded 21 new drug discovery alliances in 2007. Overall 40 per cent of GSK’s pipeline is derived from licensing, acquisition, or other types of [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
